Vanda Pharmaceuticals (NASDAQ:VNDA) Director Charles Cliff Duncan Buys 5,803 Shares of Company Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Cliff Duncan purchased 5,803 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was purchased at an average price of $3.80 per share, with a total value of $22,051.40. Following the acquisition, the director directly owned 108,701 shares of the company’s stock, valued at $413,063.80. This trade represents a 5.64% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Charles Cliff Duncan also recently made the following trade(s):

• On Wednesday, November 4th, Charles Cliff Duncan acquired 3,447 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $13,167.54.
• On Tuesday, November 3rd, Charles Cliff Duncan acquired 750 shares of Vanda Pharmaceuticals stock. The shares were purchased at an average price of $3.80 per share, for a total transaction of $2,850.00.

Vanda Pharmaceuticals Stock Down 7.5%

NASDAQ VNDA traded down $0.29 on Thursday, reaching $3.59. 1,239,112 shares of the stock traded hands, compared to its average volume of 1,499,630. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.54. The company has a fifty day moving average price of $4.70 and a 200-day moving average price of $6.16. The company has a market cap of $217.09 million, a price-to-earnings ratio of -0.78 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 12 month low of $3.57 and a 12 month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The business had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million. As a group, research analysts forecast that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current fiscal year.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought shares on November 3, 4 and 5, investing about $38,000 in total and increasing his stake. The purchases may signal confidence in Vanda’s prospects. SEC filing
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and raised its FY2026 loss estimate to $2.45 per share from $3.03, while improving its Q4 2026 estimate. That outlook is partly offset by a wider projected FY2027 loss of $1.02 per share, versus $0.94 previously.
• Negative Sentiment: HC Wainwright lowered its loss-per-share forecasts for Q2, Q3 and Q4 2027, suggesting weaker earnings expectations for much of that year. VNDA is also trading near its 12-month low and below its 50- and 200-day moving averages, reflecting continued share-price weakness.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth $46,841,000. Renaissance Technologies LLC increased its position in Vanda Pharmaceuticals by 11.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company’s stock valued at $25,979,000 after buying an additional 378,598 shares in the last quarter. State Street Corp increased its position in Vanda Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after buying an additional 500,843 shares in the last quarter. AIGH Capital Management LLC increased its position in Vanda Pharmaceuticals by 37.6% during the 1st quarter. AIGH Capital Management LLC now owns 2,750,000 shares of the biopharmaceutical company’s stock valued at $19,002,000 after buying an additional 751,569 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in Vanda Pharmaceuticals by 25.0% in the first quarter. Quantinno Capital Management LP now owns 327,193 shares of the biopharmaceutical company’s stock valued at $2,261,000 after buying an additional 65,391 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Wall Street Analysts Forecast Growth

VNDA has been the subject of several recent research reports. B. Riley Financial restated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Zacks Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Oppenheimer initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective on the stock. HC Wainwright reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.